26 / 27
Page 75
Journal of Biotechnology & Biomaterials | ISSN: 2155-952X | Volume: 8
July 23-24, 2018 | Vancouver, Canada
Annual Biotechnology Congress
Nanosystems formed by amphiphilic antimony(v) complexes incorporating amphotericin B for the
treatment leishmaniasis
Arshad Islam
Universidade Federal de Minas Gerais, Brazil
T
his work aimed to develop an oral formulation of amphotericin B (AmB) for treatment of leishmaniasis. AmB is an antifungal and
antibacterial macrolide polyene derived from
Streptomyces nodosus
strain, that belongs to the group of second generation anti-
leishmanial drugs and is extensively used in case of failures in the treatment with antimonial compounds. AmB was incorporated into
nano-systems formed by amphiphilic antimony (V) complexes with ligands of alkyl methyl glucamide series (L8 and L10, with 8 and
10 carbon chain, respectively). Incorporation rate of 0.2% AmB into SbL8 and SbL10 dispersions was determined using an HPLC-
based technique and was found to be 84±1% and 74±1%, respectively. The characterization of SbL10-AmB and SbL8-AmB by circular
dichroism and UV-visible spectroscopies showed that AmB is present predominantly under the monomeric form in both SbL8 and
Sb10 nanosystems, which is the least toxic form to the host and potentially most bioavailable. The potential for the oral treatment
of visceral (VL) and cutaneous leishmaniasis (CL) was evaluated in murine models in comparison to the standard drug Anforicin
B® or Glucantime® administered intraperitoneally or orally. In Balb/c mice infected with Leishmania amazonensis, the SbL10-AmB
mixed formulation (170 mg Sb/kg and 14 mg AmB/kg, each two days by oral route) resulted in a significant decrease of the lesion
size, when compared to orally administered Glucantime® and SbL10 (170 mg Sb/kg, each two days), Anforicin B® (>1mg/kg/each 5th
day, by intraperitoneal route) and control saline group. In Balb/c mice infected with Leishmania infantum, both the SbL10-AmB and
SbL8-AmB mixed formulations given orally (170 mg Sb/kg and 14 mg AmB/kg per day) reduced significantly the parasite load in the
liver compared to the untreated control, to a similar level as AmB given intraperitoneally (0.9 mg/kg/day). This study established for
the first time the potential of mixed SbL10-AmB and SbL8-AmB formulations for the oral treatment of both cutaneous and visceral
leishmaniasis, indicating their potential for further development and applications.
arshad.cgl@gmail.com; arshad@ufmg.brJ Biotechnol Biomater 2018, Volume: 8
DOI: 10.4172/2155-952X-C3-095